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Background: Molecular tools are very sensitive and specific and could be an alternative for the diagnosis of
malaria. The complexity and need for expensive equipment may hamper implementation and, therefore,
simplifications to current protocols are warranted.
Methods: A PCR detecting the different Plasmodium species and differentiating between Plasmodium falciparum
and Plasmodium vivax was developed and combined with a nucleic acid lateral flow immuno-assay (PCR-NALFIA)
for amplicon detection. The assay was thoroughly evaluated for the analytical sensitivity and specificity in the
laboratory, the robustness and reproducibility in a ring trial and accuracy and predictive value in a field trial.
Results: The analytical sensitivity and specificity were 0.978 (95% CI: 0.932–0.994) and 0.980 (95% CI: 0.924-0.997),
respectively, and were slightly less sensitive for the detection of P. vivax than for P. falciparum. The reproducibility
tested in three laboratories was very good (k = 0.83). This evaluation showed that the PCR machine used could
influence the results. Accuracy was evaluated in Thailand and compared to expert microscopy and rapid diagnostic
tests (RDTs). The overall and P. falciparum-specific sensitivity and specificity was good ranging from 0.86-1 and
0.95-0.98 respectively, compared to microscopy. Plasmodium vivax detection was better than the sensitivity of RDT,
but slightly less than microscopy performed in this study.
Conclusion: PCR-NALFIA is a sensitive, specific and robust assay able to identify Plasmodium species with good
accuracy. Extensive testing including a ring trial can identify possible bottlenecks before implementation and is
therefore essential to perform in additon to other evaluations.* Correspondence: p.mens@kit.nl
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The correct and timely diagnosis of life-threatening dis-
eases such as malaria is essential for the initiation of ac-
curate and prompt treatment [1]. However, correct
diagnosis of infectious diseases is often difficult in
resource-poor settings, resulting in clinical decisions
based on presumptive diagnosis [2]. This can lead to un-
necessary over-treatment of one disease and under-
recognition of another [3]. The diagnosis of malaria is
often complicated by the fact that routine microscopy
has a relatively low detection limit, is time-consuming
and requires experienced microscopists to obtain reliable
results [4]. Rapid diagnostic tests (RDTs) could be a good
alternative but the detection limit is currently even lower
than microscopy, especially when the infecting agent is
non-falciparum. RDTs specifically detecting Plasmodium
vivax for instance can have a very low sensitivity [5,6].
Molecular diagnostic tools, such as PCR, are highly
sensitive and specific but involve sample processing.
The read-out of the assay requires either laborious gel-
electrophoresis, which uses toxic products and UV-light
or expensive equipment to measure the assay in real time
[7]. Simplifying this methodology is thus warranted and
has been partly achieved by using, for example, isother-
mal amplification technologies such as LAMP [8] or sim-
ple and cheap read-out systems, such as nucleic acid
lateral flow immuno-assay (NALFIA) [9,10], which can
circumvent the use of electrophoresis or the purchase of
expensive real-time PCR machines. NALFIA is analogous
to an RDT but instead of detection of antigens it will de-
tect amplified nucleic acids. Like an RDT the sample pip-
etting is fast, the results can be kept for further reference
after the test is performed and the waiting time before
the result can be visually read is only 10 minutes without
the need of UV light and ethidium bromide.
Essential to the development of a new diagnostic test is
determining the accuracy in diagnosing the right condi-
tion [11]. Therefore, high sensitivity (the probability of a
positive test result for a patient with the disease) and spe-
cificity (the probability of a negative test for a patient that
does not have the disease) is required [12]. All new diag-
nostic tests need to be assessed for these characteristics.
This entails a comparison with the gold or reference
standard that should be infallible. This is difficult in the
case of malaria because the obvious reference standards,
microscopy and RDT, which are routinely used in the
field, are not as sensitive as molecular tools, leading to an
underestimation of the specificity of the molecular assay.
Nevertheless, in order to estimate the accuracy of a
diagnostic test it has to undergo different testing phases
[13,14]. During the first phase a small study is performed
on typical patients with and without the disease of inter-
est, and the analytical sensitivity and specificity is
assessed. If it fails this phase than the test is not worthfurther exploring without significant modifications. Dur-
ing the second evaluation phase in which the diagnostic
sensitivity and specificity are assessed, a large number of
patients are tested. The patient sample should be repre-
sentative of the target population. Although these results
might give a good reflection of the sensitivity and speci-
ficity, it is also essential to study the reproducibility and
ruggedness of a test when other operators perform the
assay. Although with the ideal test the performance is
not operator-dependent, many tests show variation when
performed in different laboratories [14]. Having the test
performed by different operators and/or different labora-
tories will reveal whether the test is reproducible or not
[15], and whether a large rollout would be a feasible
aim. This can be studied in a so-called ring trial.
This study describes the development of a species-
specific PCR combined with NALFIA for the detection
of pan-Plasmodium species and the discrimination be-
tween Plasmodium falciparum and P. vivax. In addition
the test has been evaluated for the accuracy in an ex-
ploratory study in the laboratory and thereafter validated
in Mea-Sot Thailand for accuracy in the final target
population. Reproducibility was assessed by evaluating
the assay in a ring trial in three different laboratories
that did not participate in the development of the assay.
Methods
DNA isolation and PCR
DNA was extracted, with Qiagen DNA mini kit (Qiagen,
Germany) according to the manufacturer’s instructions,
from all the whole blood samples used in this study. For
each sample 200 μl of whole blood was used and the
samples were eluted in 200 μl TE buffer. The PCR re-
action consisted of primers (Table 1), targeting the 18S
gene of Plasmodium and the human housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), which was used as an internal control. For
the discrimination of two Plasmodium species, general
pan-Plasmodium and specific P. falciparum and P. vivax
forward primers were designed. As a reverse primer, a
generic primer developed on a conserved region present
in all three targets, was used. The PCR reaction with a
final reaction volume of 25 μl comprised of 12,5 μl 1X
Qiagen Multiplex PCR Master mix (Qiagen, Germany),
200 μM dUTP, 2% DMSO, 1U UNG (Fermentas), pri-
mers in the concentration as presented in Table 1, and 2
μl template DNA. The cycling conditions consisted of an
nitial step of 10 min at 50°C followed by one step of
15 min at 95°C, 35 cycles of 45 sec at 94°C, 45 sec at
54°C and 60 sec at 72°C and a final step of 10 min at
72°C. For each experiment a blood sample negative for
Plasmodium, a sample containing P. falciparum, a sam-
ple containing P. vivax and a non-template control of
only water were used as control samples.
Table 1 Overview of the primer sequences and used concentrations in the PCR-NALFIA reaction
Target Primer type Sequence Product size (bp) Concentration in PCR mix (nM)
GAPDH Forward Biotin-5’ TGCACCACCAACTGCTTAGC -3’ 90 75
GAPDH Reverse Texas Red-5’ GGCATGGACTGTGGTCATGAG -3’ 75
Pan-Plasmodium Forward Digoxigenin-5’ TCAGATACCGTCGTAATCTTA -3’ 180 50
Pan-Plasmodium Reverse * Biotin-5’- AACTTTCTCGCTTGCGCG -3’ 900
P. falciparum Forward FAM-5’ GTCATCTTTCGAGGTGACTT -3’ 100 200
P. vivax Forward DNP-5’ TTTCTCTTCGGAGTTTATTC -3’ 100 650
* This primer was used as a reverse primer for the P. falciparum and P. vivax reaction as well.
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A nitrocellulose membrane of 120 mm (Millipore, Am-
sterdam, The Netherlands) was used for the preparation
of the NALFIA. On the nitrocellulose, 0.8 mg/ml anti-
Texas Red rabbit IgG fraction (Invitrogen, Paisley, UK),
0.2 mg/ml anti-Digoxigenin polyclonal antibody (Roche
Diagnostics, Mannheim, Germany), 0.4 mg/ml anti-
dinitrophenyl- rabbit IgG fraction, (Invitrogen, Paisley,
UK), and 0.1 mg/ml anti-FITC purified polyclonal anti-
body rabbit polyclonal IgG, (AbD Serotec, Oxford, UK)
were sprayed, all at 0.8 μl/cm and within 4.5 mm distance
of each other. A Surewick G041 glass-fibre sample pad
(Millipore, Billerica, USA) was used to spray 2.5 μl/cm
streptavidin-labelled carbon suspension (three parts
streptavidin-labelled carbon and two parts sodium tetra-
borate buffer solution containing 6.25% sucrose and
6.25% BSA) and attached to the NALFIA stick. The strips
were air dried at 37°C, packed in plastic housing and
sealed in airtight bags containing silica until further use.
After amplification 5 μl PCR product and 70 μl running
buffer (0,1 M borate buffer pH 8.8, 1% BSA and 1% (v/v)
sodium azide) were added to the sample pad of the NAL-
FIA and after 10 min the results were read. The NALFIA
was considered valid if a black line at the GAPDH position
was visible. If in addition to the GAPDH line, the pan line
was present then the sample contained PlasmodiumTable 2 Overview of the origin and number of samples used
evaluations
Origin of the samples
Wad Medani Teaching Hospital, Sudan P. fa
Malaria Reference Laboratory, London








Academic Medical Centre, The Netherlands, returning travellers Neg
Dutch Blood Bank Neg
Culture of P. falciparumDNA. If in addition the P. falciparum line was present
then a P. falciparum infection was confirmed. The same
held for the P. vivax line in combination with the pan-
Plasmodium line. If all four lines were present than it was
considered to be a mixed infection. If no line appeared on
the GAPDH position, regardless of other lines that might
have appeared, the NALFIA test was considered to be a
test failure. An example of the different possibilities of the
NALFIA outcomes is shown in Figure 1.Laboratory evaluation PCR-NALFIA
The analytical sensitivity of the PCR-NALFIA test was
assessed by using a 5% P. falciparum NF54 ring stage
culture (in 5% haematocrit). The cultured parasites were
10-fold diluted with Plasmodium-negative donor blood
to obtain malaria parasites dilutions from 0.55% to 5x10-
8% in 45% haematocrit. The specificity of the test was
determined by analysing malaria positive and negative
samples (n = 241) from: i) travellers returning from
malaria-endemic areas, diagnosed by an experienced
technician by microscopy and/or Plasmodium-specific
nested PCR according to Snounou et al. [16]; ii) from
Sudanese patients with a confirmed P. falciparum infec-
tion; and, iii) samples provided by the Dutch blood bank
which excludes donations of patients who travelled inin the laboratory (n = 241) and ring trial (n = 94)
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Figure 1 Examples of the different test outcomes of the PCR-NALFIA. a) No control and no test line are visible. This is a test failure but can
also be seen when only water is amplified (negative control) b) A positive control line and a negative test line are visible indicating that the test is
valid but that no parasite DNA is detected c) Next to the control a Plasmodium line and a specific line for P. falciparum is present indicating a
P. falciparum infection d) Next to the control and Plasmodium line the specific line for P. vivax is visible indicating a P. vivax infection. e) Both a positive
control and a positive test line for Plasmodium are visible indicating a valid test positive for Plasmodium but negative for P. falciparum and P. vivax.
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therefore be considered negative for malaria (Table 2).
Inter-laboratory evaluation PCR-NALFIA
In order to assess the inter-laboratory variability of the
assay, a diagnostic ring trial was performed. All necessary
reagents and 94 processed samples were sent to three la-
boratories that were not directly involved in the develop-
ment of the current PCR and NALFIA technology. These
materials were accompanied by a protocol on how to
perform the assay but no further training was given. The
laboratories used their own PCR equipment and the
assay was performed by personnel who had previousexperience performing PCR. In addition to the patient
samples presented in Table 2 two DNA samples of pure
P. falciparum culture of 10 and 1 p/μl were provided.
The protocol indicated that two non-template controls
should be added by the laboratory performing the assay.
The technicians performing the assay were blinded as to
the contents of the samples and the performance of the
other laboratories in the trial.
Field evaluation of PCR-NALFIA, study site and
patient description
A prospective study was conducted in the health clinics
of Wang Pa and Mae Khon Ken, Mae Sot district, Tak
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Myanmar border. In this hill-forested region, with low
year-round transmission and two seasonal peaks from
May-September during the rainy season and December-
January, the predominant species causing malaria are P.
vivax and during the rainy season P. falciparum [17].
Patients were recruited in the malaria clinics of Wang Pa
and Mae Khon Ken located around Mae Sot. Samples
were transported to the Shoklo Malaria Research Unit
(SMRU) in Mae Sot for further processing. Ethical ap-
proval for the evaluation in Thailand was obtained from
the local ethical review board, Mahidol Oxford Research
Unit and the Oxford Tropical Research Committee.
Patients visiting the outpatient clinics with the clinical
suspicion of uncomplicated malaria, over three years old,
and willing to participate in the study, were enrolled after
obtaining their informed consent or in the case of minors
that of their parents or guardians. Additional inclusion
criteria were axillary temperature ≥ 37.5°C or a history of
fever in the previous 24 hours.
From each participant, finger prick blood was collected
in EDTA tubes (Stastedt, Numbrecht, Germany) for
preparation of thin and thick Giemsa-stained microscopy
slides, to perform a HRP-2 and PAN pLDH-based RDT
and 200 μl of blood was used for DNA isolation. Micros-
copy was performed according to international and GCP
guidelines by local expert microscopists [18]. Parasites
were counted against 500 leukocytes at 1,000x magnifica-
tion. If only one parasite was found after counting of 500
WBC then counting continued until a second parasite
was observed with a limit of counting 4,000 WBC. All
slides were read by two microscopists and discordant
results were read by a third reader. A leukocyte count of
8000/μL was assumed to calculate the parasite density
per μl and the final result was the geometric mean of the
readings. Peripheral blood was applied to the SD Bio Line
Malaria Antigen P.f/Pan POCT RDT (Standard Diagnos-
tics Inc) according to the procedures described by the
manufacturer. The PCR-NALFIA was performed as
described above. All test operators were blinded to each
other’s test results. On the discordant results and a selec-
tion of the microscopy negative samples (n = 71) an add-
itional diagnostic nested PCR was performed as
described by Snounou et al. [16].
Data analysis
Data from the laboratory evaluation and the ring trial
were directly entered into Excel. Data from the field
evaluation were collected on separate case record forms
and subsequently entered in Excel. Calculations of sensi-
tivity, specificity and agreement between microscopy,
RDT and PCR-NALFIA were done using Epi Info version
6.04 (Center for Disease Control and Prevention, Atlanta,
GA, USA). For the ring trial analysis a combined kappawas calculated by using the formula for more than two
raters and more than two outcomes as described by
Fleiss et al. [19]. Each of the samples was rated into one
of the six subtypes (P. falciparum, P. vivax, negative,
P. falciparum and P. vivax mixed infection, non-P. falcip-
arum and non-P. vivax infection or water controls) by
the three laboratories. Kappa (κ) values express the
agreement beyond chance and were calculated with a
95% confidence interval. Kappa was calculated for each
of the subtypes separately against an amalgam of the
remaining categories. For example, the P. falciparum
kappa is the two-rating kappa where P. falciparum is
positive and all remaining outcomes are negative. The
combined kappa is the appropriately weighted average of
the individual kappas. There is considerably more agree-
ment about the rating of samples as being P. falciparum
compared to P. falciparum/P. vivax. A ĸ-value [20] of
0.21-0.60 is a moderate, a ĸ-value of 0.61-0.80 a good
and a ĸ-value >0.80 is an almost perfect agreement be-
yond chance. Kappas were calculated by STATA SE11.2
Results
Analytical performance of the PCR-NALFIA
The analytical sensitivity could only be assessed for
P. falciparum as there was no reference sample with
P. vivax available with a certified number of parasites.
The analytical sensitivity was 1 p/μl for both the Pan-
band and the P. falciparum band with the P. falciparum
sample. The samples were also once run on agarose gel
to confirm the expected amplicon size of both GAPDH
and the Plasmodium fragments.
The phase 1 evaluation of 241 samples resulted in three
test failures (two in negative controls and one P. falcip-
arum-positive sample), meaning that no GAPDH line
could be observed. Of the negative samples, five were
found positive by PCR-NALFIA for P. falciparum, of
which two were also positive in the pan-Plasmodium line.
None of the negative samples reacted with the P. vivax
line. All P. falciparum samples reacted with both the pan-
Plasmodium and P. falciparum line, including the sample
that had no GAPDH line. None of the samples reacted
with the P. vivax line. All P. vivax samples were positive
for pan-Plasmodium but three failed to react with the spe-
cific P. vivax line. None reacted with the P. falciparum
line. Of the 18 Plasmodium malariae samples, three were
negative and one indicated a P. vivax infection. All
Plasmodium ovale samples, including the P. falciparum/
P.ovale mixed infections were identified correctly. The
P. falciparum/P.vivax mixed infection samples were all
positive for pan-Plasmodium and P. falciparum but one
failed to detect the additional P. vivax line.
To determine sensitivity and specificity, the test fail-
ures were excluded and microscopy results were used as
the reference. The overall sensitivity and specificity for
Table 4 Levels of agreement between different
laboratories in the ring trial for the detection and
differentiation of Plasmodium species with PCR-NALFIA
K values*
Laboratory 1 Laboratory 2 Laboratory 3
Reference 0.90 0.94 0.84
Laboratory 1 - 0.92 0.80
Laboratory 2 - - 0.76
Laboratory 3 - - -
*The k values represent the agreement beyond chance between each
laboratory and the reference and between two laboratories.
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line in this specific data set was 0.978 (95% CI: 0.932–
0.994) and 0.980 (95% CI: 0.924-0.997) respectively. For
the detection of P. falciparum through the specific P. fal-
ciparum line, the sensitivity and specificity in this set was
1 (95% CI: 0.946-1) and 0.967 (95% CI: 0.921–0.988). The
sensitivity of the P. vivax line was lower in this evaluation
(0.857 (95% CI: 0.664-0.953)) but the specificity was good
(0.995 (95% CI: 0.969-0.999)).
Intra-assay variability between three independent
laboratories
Of the 96 samples that were tested by the three different
laboratories, 84 were identified correctly by all three la-
boratories. Table 3 gives an overview of the score of cor-
rect answers per individual laboratory. One sample
containing P. falciparum was scored as a test failure in
all three laboratories. In addition, laboratory 1 identified
two negative samples as a P. falciparum infection, one P.
vivax sample as negative and another P. vivax sample as
a mixed infection with P. falciparum. Laboratory 2 had
only two additional misdiagnoses. One negative sample
was interpreted as a non-P. falciparum/non-P. vivax
sample and one P. vivax sample was interpreted as a
mixed infection with P. falciparum, which was the same
sample that was misdiagnosed with the same interpret-
ation as laboratory 1. Laboratory 3 scored the least of
the three laboratories. Three samples that were positive
for either P. falciparum, P. vivax or P. ovale were scored
negative. One negative sample was interpreted as posi-
tive for P. falciparum, a P. vivax and a P. falciparum
sample were both identified as non-P. falciparum/non-P.
vivax and a P. falciparum/P. vivax co-infection was
interpreted as a P. falciparum mono-infection. Despite
these discrepancies, the overall agreement between la-
boratories and the reference panel was good to almost
perfect. The kappa amongst the different laboratories
can be found in Table 4. The agreement between theTable 3 Results of the ring trial per sample type and
laboratory
Sample type Laboratory 1 Laboratory 2 Laboratory 3 Kappa
P. falciparum 12/13* 12/13* 10/13* 0.873
P. vivax 7/9 8/9 7/9 0.727
P. ovale 4/4 4/4 3/4 0.836^
P. malariae 4/4 4/4 4/4
P. falciparum/P. vivax 1/1 1/1 0/1$ 0.497
Negative# 61/63 62/63 62/63 0.858
> Including two P. falciparum culture samples.
*One sample failed in all three laboratories.
# The two water controls the laboratories added themselves are not presented
in the table.
$ This sample was identified as a P. falciparum mono-infection.
^ The results for P. ovale and P. malariae samples were scored as positive,
non-falciparum, non-vivax and are therefore combined in the analysis.different samples was also good and can be seen for the
different species in Table 3. The overall kappa was 0.839.
Only the P. falciparum/P. vivax mixed infection agree-
ment is very low but this is caused by the fact that only
one sample of this type was analysed.
Field evaluation of the PCR-NALFIA in a malaria-endemic
setting
The evaluation of the PCR-NALFIA took place between
December 2011 and January 2012. In total, 381 patients
were included of which 85 patients were seen in Mae
Khon Ken and 296 in Wang Pa. The mean age of the
participants was 20.6 years (range four to 63 years), 33%
was female and 67% was male, which is representative
for the region. In total, 274 of the patients recruited into
the study were found to be negative with microscopy, 72
were found to be harbouring P. vivax, (mean parasit-
aemia 730 p/μl), 32 P. falciparum (mean parasitaemia
5185 p/μl) and three a mixed infection. A complete
overview of the results can be found in Table 5. When
RDT is compared to microscopy, RDT had four test fail-
ures and detected a substantially lower number of P.
vivax cases than microscopy (14 of 72 microscopy con-
firmed P. vivax were missed). The PCR-NALFIA
detected more positive samples than were found nega-
tive with microscopy. Three were identified as P. falcip-
arum, six were identified as P. vivax and five others as a
mixed infection. The 14 samples that were negative for
P. vivax with PCR-NALFIA were the same that were
negative with RDT. Seven of these samples had a para-
sitaemia below two parasites/ μl, four samples between
four parasites/μl and 10 p/ul and three between 20 p/μl
and 32 p/μl. The calculated sensitivity and specificity of
the different detection lines of the PCR-NALFIA com-
pared to the different assays can be found in Table 6.
When only the microscopy positive samples are com-
pared to the RDT and PCR-NALFIA results and strati-
fied to parasitaemia, it is found that PCR NALFIA is
able to reliably detect samples with a parasitaemia of
over 50 p/μl whereas RDT is already having problems
with identifying some of the samples below 500 p/μl, as
Table 5 Overview of results of the field evaluation in Thailand
Microscopy RDT PCR-NALFIA Total
Negative P. falciparum P. vivax Mixed infection
Negative 260 3 6 5 274
Negative 257 * 2 6 5 266
P. falciparum 3 1 4
P. falciparum 32 32
P. falciparum 32 32
P. vivax 14 57 1 72
Negative 14 4 1 19
P. falciparum 1 1
P. vivax 52 52
P.f + P.v 1 1 2
P. falciparum 1 1 2
P.m+ P.v 1 1
Negative 1 1
Total 274 36 63 8 381
*including four RDT test failures.
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were analysed with a nested PCR, the three PCR-
NALFIA positive P. falciparum samples were confirmed
(including the RDT positive sample) to be positive for
P. falciparum; three of the P. vivax samples were con-
firmed to contain P. vivax, however the other three were
negative; of the mixed infection, two were found nega-
tive and three were found to have only P. vivax. Thirteen
out of the 14 samples that were identified as P. vivax
positive by microscopy but both PCR-NALFIA and RDT
negative were positive in the nested PCR. The other
sample was negative. In the group of negative samples






SD-Bioline vs Microscopy (n = 377) 0.813 (0.723-0.879) 0.985 (0.96
Microscopy vs PCR-NALFIA (n = 381) 0.869 (0.787-0.924) 0.949 (0.91
SD-Bioline vs PCR-NALFIA (n = 377) 0.822 (0.734-0.887) 0.989(0.965
P. falciparum
SD-Bioline vs Microscopy (n = 377) 1 (0.874-1) 0.985 (0.96
Microscopy vs PCR-NALFIA (n = 381) 0.773 (0.617- 0.880) 1 (0.986-1)
SD-Bioline vs PCR-NALFIA (n = 377) 0.796 (0.642-0.897) 0.988 (0.96
P. vivax*
SD-Bioline vs Microscopy (n = 338) 0.722 (0.602-0.818) 1 (0.982-1)
Microscopy vs PCR-NALFIA (n = 381) 0.845 (0.735-0.916) 0.951 (0.92
SD-Bioline vs PCR-NALFIA (n = 338) 0.754 (0.633-0.846) 1 (0.982-1)
*Because the pLDH line on the SD-bioline RDT also detects P. falciparum, all P. falcip(21%) were identified as P. vivax positive and no other
species were found.
Conclusion
This paper describes the development of a multiplex
PCR assay for the detection and differentiation of mal-
aria parasites combined with NALFIA to enable fast and
easy readout of the results. This assay has been shown
to be sensitive and specific and the readout with NAL-
FIA is straightforward.
The assay was evaluated in three different phases.
First, the analytical sensitivity and specificity was








0-0.995) 0.956 (0.884-0.986) 0.930 (0.892-0.956) 0.83
4-0.970) 0.869 (0.787-0.924) 0.949 (0.914-0.971) 0.82
-0.997) 0.967 (0.900-0.991) 0.934(0.897-0.958) 0.85
4-0.994) 0.872 (0.718-0.952) 1 (0.986-1) 0.92
1 (0.874-1) 0.971 (0.946-985) 0.88
7-0.996) 0.898 (0.748-0.967) 0.973 (0.948-0.987) 0.84
1 (0.914-1) 0.930 (0.892-0.956) 0.78
0-0.972) 0.80 (0.689-0.880) 0.964 (0.935-0.981) 0.78
1 (0.914-1) 0.941 (0.905-0.964) 0.82
arum samples were excluded from the analysis with SD-Bioline.
Table 7 Sensitivities of SD-Bioline and PCR-NALFIA
compared to microscopy differentiated in parasitaemia
Parasitaemia SD Bioline PCR-NALFIA
> 50.000 / μl 100% (3 / 3) 100% (3 / 3)
5000 to 50.000 / μl 100% (49 / 49) 100% (49 / 49)
500 to 5000 / μl 100% (22 / 22) 100% (22 / 22)
100 to 500 / μl 81.8% (9 / 11) 100% (11 / 11)
50 to 100 / μl 66.7% (2 / 3) 100% (3 / 3)
< 50 / μl 10.5% (2 / 19) 26.3% (5 / 19)
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detection of P. falciparum which is likely caused by the
lower parasite densities present in a P. vivax sample.
Next, the robustness, reproducibility and repeatability
of the assay was tested in the ring trial. This phase is
often not performed in diagnostic test development and
evaluation but it can give extremely valuable results. The
current trial has shown, for example, that although in
general the reproducibility of the assay was acceptable,
there were differences in the results. Laboratory 3 failed
to correctly identify some of the samples. Although the
overall agreement between the laboratories was good, it
was striking that laboratory 3 identified more samples as
negative or a mono-infection, pointing to a reduced sen-
sitivity of the assay in this laboratory. The exact mechan-
ism behind this reduced sensitivity in this laboratory was
not further investigated and can be the result of a variety
of factors altough all reagents, samples and materials
were provided to the laboratory and were the same as
the other laboratories received. It should be noted that
this was the only laboratory that performed the amplifi-
cation on a Biorad-CFX Real-Time PCR machine,
whereas the other laboratories used conventional PCR
machines. The Real-Time machinery has a variable
ramping time which can be installed manually whereas
the other conventional PCRs have fixed ramping times
and are therefore comparable in this respect. It was
however not investigated whether or not the Real-Time
PCR machine was the cause of the slightly poorer results
but it cannot be excluded. This issue would not have
would not have surfaced if a ring trial had not been per-
formed. In all three laboratories and in the field evalu-
ation, use of the NALFIA as a readout system was
received enthusiastically by performers and was carried
out without any particular difficulties.
In the final field evaluation, the sensitivity, specificity
and predictive value of the assay was studied in a moder-
ate transmission area for P. falciparum and P. vivax
parasites. In this study the results of PCR-NALFIA were
compared to both microscopy and RDT. Although mi-
croscopy is often considered to be the gold standard, it
is not sensitive enough compared to PCR or other mo-
lecular diagnostics and may consequently obscure theresults of the specificity of the assay under investigation
[15]. RDTs are even less sensitive but were used in this
study to compare the performance of the PCR-NALFIA
with another assay that is used on a day-to-day basis [6].
Because of these limitations the discordant results were
also analysed by a sensitive nested PCR. This study
showed that PCR-NALFIA performs very well for the
detection of P. falciparum and is as sensitive and specific
as microscopy and PCR. The assay was also very sensi-
tive compared to RDT and was able to pick up all sam-
ples over 50 parasites/ul that were found positive in
microscopy. For P. vivax, the microscopy performed in
this study was more sensitive although some samples
that were found negative with microscopy were found
positive in PCR and confirmed positive with the nested
PCR as well. The microscopy performed extremely well
in this study and it is therefore essential to mention that
the protocol used for slide reading is different from the
one that is used as standard in routine care, and which
is usually less sensitive.
While it was not observed in the present study, a pos-
sible concern might be the risk of contamination when a
PCR sample is transferred to the NALFIA device.
Altough this could partly be circumvented by perform-
ing the PCR set up and amplification in one room and
do the read-out in another, a closed system in which no
leakage to the environment is possible should be the
next step in the development. Another current disadvan-
tage is that this assay relies on PCR technology for amp-
lification, which demands electricity. This does not have
to be a problem if the assay is going to be performed in
a setting where constant supply of electricity can be
guaranteed. However, if one desires to use this assay in
more remote settings in which no constant supply of
electricity is available, alternative platforms that are less
dependent on electricity, such as LAMP [21] or NASBA
[22], could be considered. Nevertheless, although these
assays are generally considered to be sensitive and spe-
cific they should be subjected to a thorough analysis on
their robustness, reproducibility, repeatability and user-
friendliness before implementation can be considered.
The current NALFIA strips were produced by a manu-
facturer specialized in the production of lateral flow
devices and because of the large amount of strips pro-
duced the price for the NALFIA strips is around €0,50
cent. The final costs will depend on the quanitity of
devices produced. This will also depend on the shelflife
of the NALFIA devices. This has not been extensively
studied in this study but the devices used were perform-
ing well up to a period of 6 months after dispatching at
room temperature.
Even though all reagents and materials were provided
by the developers of the assay and the technicians that
performed the assay, in both the ring trial and laboratory
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ques, no training on the current protocol was given.
This shows PCR-NALFIA is a user friendly procedure
that can be performed with no or little extra training.
The assay in its current format, or slightly modified
with more sensitive detection of P. vivax, could be an
excellent tool for epidemiological studies on prevalence
or distribution of parasites. In addition, it could be used
as a screening tool at regional level for malaria control
programmes especially in countries with declining trans-
mission [23]. Molecular tools have been shown to be es-
pecially valuable in areas where there is moderate to
little transmission [24] and PCR-NALFIA may be a
straightforward method to implement.
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